Spexis Provides Business Update and Announces Financial Results for the Full-Year 2021
- Successful launch of Spexis AG as a reverse merger of Polyphor AG with EnBiotix Inc.
- Successful closing of a USD 12.8 million pre-merger financing
- First patient enrollment and start of Phase 1 trial for inhaled murepavadin
- Start of COPILOT, the first part of the Phase 3